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CHAPTER I 
INTRODUCTION 
Chlorpromazine. an amine derivative of phenothiazine, was synthe-
sized by Charpentier of the Rhone-Poulenc Research Laboratories in 
France in 1950 (1). This compound, N,N-dimethyl*1Jilino~ropyl chloro-
phenothiazine, was found to exert a number of pharmacological effects 
involving the central and autonomic nervous systems. Its possible 
pharmacological activities attracted widespread interest and Courvoisier 
et al. (2) published an extensive report on the ph~rmacological activity 
of chlorpromazines in animals. The most striking aspect of ~his drug 
was its therapeutic value in patients with certain emotional disturb-
ances. This discovery provided the initial stimulus for the develop-
ment and ~se of phenothiazine drugs in psychiatric practice. 
A large amount of research has been conducted on the metabolism 
of chlorpromazine. The results pr~sent a picture for the site of action 
of chlorpromazi~e and the drugs metabolic fate. Domino (3) indicated 
that in low dosages chlorpromazine appears to have negligible effects 
on the cerebral cortex and specific relay nuclei of the thalamus, and 
a slight depressant effect upon the hypothalamus and limbic system. An 
interesting and apparently uni~ue effect of chlorpromazine is that of 
increasing the inhibitory effects of the activating system on sensory 
i nput. Large doses of chi orpromazine produce v~ry mild mixed depres-
sant and stimulant actions on the cerebral cortex, and also a depressant 
1 
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effect on the hypothalamus (3). In very large toxic doses, chlorpro-
mazine appears to have a direct stimulant effect upon the limbic system. 
This does not appear to be essential for its tranquilizing properties, 
but is related to toxic manifestations. Extensive work has been per-
formed on the relattonship of chlorpromazine action to concentration of 
production of brain amines, oxidative metabolism, ACTH, and cell mem-
branes. What tjlese findings mean in terms of an explanation of the 
therapeutic action of these age~ts and their derivatives, is still not 
clear. Some of these studies reflect a genuinely creative attempt t o 
gain some insight into the mechanism of action of the tranquilizers. 
The determination of the complete metabolic fate of chlorpromazine 
is an unsolved problem. Reports have suggested that more than 20 
metabolites are formed, and there is the further complication that the 
bile is as important a channel of excretion as the urine (4). The 
important metabolic pathways of chlorpromazine so far reported are 
sulfoxidation, hydroxylation, and demethylation; any combination of 
the~e reactions could occur. No evidence for either thioether cleavage 
in~ or cleavage of the phenothiazine ring in metabolic studies have 
been reported (5, 6). 
In this study the attempt was made to identify specific non-
phenothiazine metabolites of chlorpromazine . that are produced in vivo 
and in vitro. A study was also made of the conjugation system of 
hydroxymetabolites of chlorpromazine. 
CHAPTER II 
REVIEW OF LITERATURE 
Consideration of the structure of chlorpromazine suggests several 
possibilities for this drugs metabolic fate. It has been shown (6) 
that the pheno't;i\iazine nucleus of chlorpromazine is susceptible to 
sulfoxidation and hydroxylation, while the N,N-dimethylaminopropyl side 
chain can be either partially or completely demethylated, or converted 
to the N-oxide. Any combination of these reactions may occur. It is 
of interest that evidence for cleavage of the phenothiazine ring has 
not been found (6). Structures of some reported metabolites of chlor-
promazine are shown in Figure 1. 
Thioethers are not usually cleaved in vivo (5), but are oxidized 
to the corresponding sulfoxide derivatives. Liver is one of the major 
tissues which metatolizes the phenothiazines. Salzman et~· (7) re-
ported in 1956 that chlorpromazine was metabolized to a sulfoxide in 
dog and man. The sulfoxide was therefore a major metabolite that 
could undergo further ~etabolic change in vitro (8, 9). Sulfoxides 
have been found to be the principal metabolic products of chlorpro-
mazine in the mouse. Upon administration of 35S-chlorpromazine to mice, 
the radioactivity in the urine was found in the forms of free sulf~te 
(3-5%), "combined sulfate" (23-48%), and the sulfoxid,e of chlorpro-
mazine (49-73%) (11). However, using 35s-chlorpromazin~ in rats, 
Emmerson et al. (10) have reported that the urine contained negligible 
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amounts of radioactive inorganic sulfate. and this suggested that, at 
least as far as the rat is concerned, the ring system in chlorpromazine 
is biologically stable. The use of 35s~chlorpromazine has shown that 
in rats 40-50% of single doses are excreted in the urine and an equiv-
alent amount in the feces, the excretion of radioactivity being complete 
in 72 hoµrs (10). About one half of the urinary radioactivity wa$ made 
up of four co~pounds, the main one (12% of the dose) being unmetabolized 
chlorpromazine. The other three were the sulfoxides of chlorpromazine 
and its mono-demethylated and di-demethylated derivatives. An enzyme 
located in a liver microsomal fraction is responsible for the sulfoxi d-
ation of phenothiazine (8). Of the various tissues of the guinea pig 
examined, only liver showed activity. The oxidative conversion of 
chlorpromazine to sulfoxides requires NADPH and oxygen in addition to 
the enzyme preparation. Gillette et al. (12) showed in 1957 that micro-
- -
somes contain a NJ\,DPH oxidizing system which gave rise to hydrogen 
peroxide. It was attractive to speculate that the hydrogen peroxide 
so produced may serve as the source of "active hydroxyl" in the oxi ..-
dative reaction. The enzyme is probably not a peroxidase. At this 
time it is not lqiown whether chlorpromazine sulfoxide is further oxi-
dized to the sulfone (6) but Rose and Spinks (13) have shown that 
methylthioaniJ.ine is oxiqized to the corresponding sulfone by mice. 
It has been reported that chlorpromazine sulfoxide but not sulfone is 
reduced to chlorpromazine by guinea pig liver homogenates under an-
aerobic conditions, and chlorpromazine sulfone is rapidly metabolized ~ 
to products of unknown structure by liver mitocondria (9), Moran 
~ al. (14) reported that the pharmacological actions of the sulfoxide 
•. 
met.abolite differed qualitatively and qua:1titatively from the parent 
6 
drug. 
The key reaction of chlorpromazine hydroxylation may be relate~, 
by mode of action, to the well established tryptophan hydroxylase in 
brain (15). Lin et al. (16) believe that hydroxylation constitutes an 
important aspect of chlorpromazine metabolism ~n man. The hydroxylated 
compounds (17), referred to as "phenols", are excreted in three iden-
tifiable forms, i.e., unconjugated or conjugated to glucuronic acid or 
to sulfuric acid. A result of this conjugation is the production of 
more polar compounds than the parent compoun~s. From chromatographic 
studies, Posner (18) had ptoposed anq Huang and Kurland (19, 20) also 
reported, that glucuronides are the major excretory products in man 
rather than sulfoxides. The degree of glucuronide conjugate formation 
varies with individuals. A higher degree of conjugation was recognized 
in patients receiving higher doses of the drug. Dutton et al. (21) 
--
found that g~ucuronide synthesis by way of enzymatic transfer of glu-
curonic acid from UDP-glucuronic acid is not restricted to the liver, 
but could occur in the renal cortex, gastrointestinal mucosa and skin. 
Treatment of human urine with ~-glucuronidase has been shown tq re-
lease the hydroxylated metabolites of chlorpromazine (16, 22, 23). 
Evidence has been obtained to show that glucuronide and hydroxy deri-
vatives c.a,n occur with the products of demethyla tion (24). The situ-
ation is further complicated by possible dihydroxylation and hydro-
xylation of the nucleus at a number of isomeric positions. The major . 
site of hydroxylation was reported to be at the 7 position (17). 
Hydroxylation reactions perform important roles in many biosynthetic 
and catabolic processes. Unfortunately, the mechanism of this enzy-
matic reaction is not known. A monooxygenase, salicylate hydroxylase, 
was isolated from a soil bacterium by Katagiric et al. (25). This 
- ,-
enzyme catalyzes the stoichiometric formation of catechol from sali-
cylate and reduced pyridine nucleotide in the presence of FAD as a 
specific cofactor. FAD apparently protects the enzyme from inactiva-
tion (2Q). 
Chlorpromazine-N-oxide was not a major metabolite of chlorpro-
mazine as it accounted for less than 1% of the dose (27). An alky-
larylamine oxygenase is probably involved in the formation of the 
N-oxide (28). 
Demethylation has been proved to be an important process in the 
rat. Labeled chlorpromazine with 14c in one of the methyl groups 
7 
showed that as much as 17% of the isotope was exhaled as carbon dioxide 
in si~ hours (29). In man both methyl groups may be removed from the 
dimethylamino group of chlorpromazine; the mono-methyl and the com-
pletely demethylated sulfoxide derivatives have been stated to be the 
major metabolites, but quantitative data are lacking (30). Removal of 
the entire dimethylaminopropyl group apparently does not occur in dogs 
(31). Ross et al. (29) have shown the mono or compiete demethylation 
of chlorprqmazi ne in vitro. Fishman et al. (30) noted that demethyl ated 
-,---
derivatives were found to account for at least two of the sulf oxide 
metabolites. Additional evidence was given in a later report to sub~ 
stantiate the formation of the desmethyl and desdimethyl sulf oxide 
metabolites of chlorpromazine (32). 
The formation or free radicals from chlorpromazine and i ts meta-
boli tes i n vivo has been considered to occur. The work of the Forrests 
et a l . (33) i ndi cated that free radical intermedi ates of chlor promazine 
appear in the urine of patients under medicat ion, and may be of 
8 
pharmacological significance. 
The enzyme systems concerned in the metabolic pathways of drugs, 
i.e., deamination, dealkylation, hydroxylation etc., are located 
principally in liver microsomes and have the remarkable requirement 
for both redµced NADP and o:x;ygen (12). In 1955, Axelrod (34) reported 
that upon fractionations of rabbit whole liver, the microsomes alone 
could metabolize amphetamine, but a very slow rate. Addition of the 
soluble fraction greatly increased the microsomal activities. This 
suggests that the microsomal activities are NADPH dependent, as the 
soluble fraction contained glucose-6~phosphate and glucose-6-phosphate 
dehydrogenase which serves as a NADPH generating system. When this 
system lacks NADPH, the microsomal activities are limited. Gaudette 
et~- (35) have studied the dealkylation of a series of foreign and 
endogenous alkylamines. They show that only those compounds exhibiting 
a high chloroform/water partition ratio at physiological pHs are de-
dkyla.ted by the microsomal system·. It is of interest that the endo-. 
genous substrates studied exhibit extremely low partition and are not 
metabolized. This suggests (30) that the microsomal enzymes are pro-
tected by a lipid barrier which is impermeable to polar compounds. 
Bousqµet (36) summarizes cofactor requirements for the microsomal 
enzymes carrying out oxidative reactions as follows; they are quite 
similar for hydroxylation, ether cleavage, dealkylation, and deamin-
ation. The pH optima are also similar, varying only slightly from pH 
7.0 to 8.5, depending on the particular substrate. NADPH is a general 
requirement for all of these reactions, as is molecular oxygen. NADH 
can not replace NADPH in the oxidative reactions. Nicotinamide is 
frequently added to homogenates to protect NADP, and Mg++ is a required 
.9 
ion,. Glucose-6-pho14phate and. .glucoee-6 .. phosphate dehyd.rogenase are 
· required to maintain NADP in the reduced ~tate •. 
·consideration has been given to the literature a13$ociated with 
' ' 
the .meta.bolism of chlorpromazine. Several importa,nt metabolic pathways 
have been elucidated for this type 4rug. A particularly characteristic 
reaction is sul.f'oxidation. Otherli! include ~droxylation, demethylation, 
N-o~ide formation, 1i1,nd conjugation of the phenols with glucuronic acid. 
' ' ' 
Evidence i:n,d:i,cates that aromatic eydroxylat:i,on ;f'oilowed by conjugation 
with glucuronio acid is the dominant metabolic pathway for the pheno-
thiazj,ne drugs in man, 1;1.nd does not necessariJ,.y result in lo_ss of 
p~armaoological activity. In view of the number of known and theoret~ 
ioal metabolites of c~lor~romazine, and the inherent lability o;f' the 
phenothiazine nucleus, one should ooriclude that the progress in eluci..-
dating·.ihe metabolic ;f'ate of ohlorpromazine has been. quite reJn~rkab],.e. 
However, ;much work remains to be done~ since no single metabolite 
identified to d1:1,te accounts fqr more than 8-10% of the dose (1). 
CHAPTER III · 
.EXPERIMENTAL 
Animal~ and '.l.'issues 
Male albino rats (300 to 460 gm) obtained from Holtzman Company 
were used for the in vivo experiments. The rats were not fasted be-
fore experiments, and following the intraveritoneal administration of 
3H-chlorpromazine, or saline solution for control, the rats were placed 
in w-ine collection cages. They receiyed water for the duration of the 
experiment. 
Fresh pig livers were purchased from Ralph's Packing Co., Perkins, 
Oklahoma. As soon as they were removed from pig, they were sectioned 
and ch:i,lled with ice. 
Reagents 
3 . . . 
H-chlorpromazine: 20 mg dissolved in 2 ml saline.solution (9 
gm/L). Source: Randomlr ;Labeled by the Wilzbach method (37) Bio-, 
chemistry Dept~, Oklahoma State University, ~tillwater, Oklahoma. 
Chlorpromazine hydrochloride. RS0i/=66p03, Smith, Kline and 
French Labs., Philadelphia,. Pennsylvania. 
Orthanilic acid. K and K Laborlil,i;ories, Inc., P:;Lainview, New Y9rk. 
Eastman Ohromagram Sheet, type K301R2. Silica Gel, without 
fluorescent indicator. Eastman Kodak Co., Rochester, New York. 
10 
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Silica Gel G. acc. to Stahl. Brinlonan Instruments Inc., Cantiague 
Road Westbury, L.I., New York. 
POPOP (1,4-bis-2-5-phenyloxazolyl-benzene), PPO (2,5-diphenylo-
xazole). Scintillation Grade, Packard Instrument Company, Inc., Box 
428, LaGrange, Illinois. 
i-Glucuronidase/Aryl Sulfatase. B grade, Calbiochem, Los 
.Angeles, California. 
Glucose-6-phosphate dehydrogenase, type VI. Sigma Chemical 
Company, 3500 Dekalb St., St. Louis 18, Missouri. 
Ethylene gl~c.ol. Fisher Scientific Company, 4102 Greenbriar 
Drive, Houston, Texas. , 
Diethylamine. Matheson Coleman and Bell, East Rutherford, New 
Je:r,sey. 
Toluene, para-chlorobenzenesulfonic acid, naphthalene. Eastman 
Organic Chemicals, Rochester 3, New York. 
Chloroform, eerie amI1lOnium nitrate, ethyl acetate, methanol. 
J. T. Baker Chemical Co., Phillipsburg, New Jersey. 
Collection and Preparation of Urine 
After the intraperitoneal administration of 3H-chlorpromazine, or 
saline solution for control, each rat's urine was collected in an 
Erlenmeyer flask containing 5 ml of toluene at each period of 24 hours 
(23). Any feces were filtered out, and the filtrate was acidified to 
pH 2 with 6 N HCl , and separated into a yolati:le and solid portion with 
a rotary evaporator. Both portions separated were used as part of a 
balance study and for the identification of specific metabolites. 
;Frepatation or Thsue Subcellula.r Fractions 
Suboellular fractions were prepared according to the method 
described by Gillette and co-workers (12). Four hundred gms or liver 
were sectioned into small pieces, then 1200 ml of 1,15% isotonic lCCl 
12 
solution cQntaining 8.0 ml of 0.02 M K2co3 was added. 'rh:i,s mixture was 
immediately homogenized for 2 minutes in a large size Waring blender at· 
full speed tq obtain the homogenate. Four ml of the homogenate was 
equivale:rit to l gm or liver. The homogenate was centrifuged in a re-
frigerated centrifuge, Model RC-2, Ivan Sorvall, Inc.~ at 10,000 X G 
(7,500-8,000 rpm) for 30 minutes •. A vo:l,.ume or 1200 ml of. supernatant 
was obtained by filtration through glass wool. This served as the 
microsomal and soluble fractions. Th;i.s Sl,\pernatant was recentrifuged 
· to separate the microsomal fraction. A Becblan ~odel-L Ultracentrifuge 
was used at 27,000 rpm .flor one and half hours. The supernatant was 
decanted and•the microsomal fraction was suspended in isotonic KCl 
solution to ma.lee a final volume of 400 ~. · One ml, of l;i.ver microsomal 
fraction suspension was equivalent to l gm or liver. All operat;i.ons 
were conducted in a cc;:>ld rQom, a.I).d all cell fractions prepared were 
kept frozen for up to 6 months without appreciable loss of the activi-
ties of N-oxidf;l.se and N,-demethylaae enzymes. 
Balancf;I Study 
Substrate Preparation for. Incubation with l,iver Microsomal Fraction 
-.-.- ~-
Five µmoles of 3H-chlorpromazine were used in the incubation mix-
ture in the in vitro l;>alance study •. 3H-chlorpromazine was dissolv1;1d in 
....-:-
95% eth~ol to make a 0.02M solution and then diluted to 0.01 M wtth 
13 
0.2 M phosphate buffer pH 7.4. 
Incubation of Liver Miorosomes with 3H..;chlorpromazine ___ ,__...,.... __ _
The assay system described by Mueller ~ ~- (38) and Shuster 
et al. (39) was followed. Two ml portions of' liver microsomal fraction, 
1 ml equivalent to 1 gm of' liver, was incubated with 0.5 ml of' 0.01 M 
3H-chlorpromazine, Q.2 ml of 0.004 M NADP,,0.2 ml of 0.1 M.magnesium 
ohloridE:l, 0.5 ml of 0.1 M nicotinamide, 9.5 ml of 0.05 M dipotassium 
glucose-6-phosphate, 0.2 ml.of glucose-6-phosphate dehydrogenase (2 
units), O.l ml of 0.25 1V1 neutralized semicarbazide, and l.O ml of 0.2 
M phosphate buffer pH 7.4, to make a final volume of' 5.3 ml. The mix-
ture was then incubated in a shaking water b.ath at 370c under an oxygen 
atmosphere. Arter one hour the mixture was heated to 70°C for 5 min-
utes to denature the enzyme and the denatured protein was removed by 
centrifugation. This incubated solution was then treated in the same 
manner as the urine collected from the in vivo experiments. 
--
F:raotionatio~ of Metabolites 
------ --- ------
Both urine sample~ and microsomal fractions· (incubated solution) 
were adjusted to pH 13 with l N Na.OH. Chlorpromazine N-oxide, sul-
f'o:x:ide, <;1.ea;J.kylated products, and unmetaboliz.ed chlorpromazirie were 
removed by extraction of' the pH 13 solution twice with three volumes 
of ch,loro.form. The reddual so;J.ution was titrated to pH 9.5 with l N 
HCl and the ••tree" phenolic metabolites of chlorproJ11azine were ex., 
tracted from this solution with two·extractions of' three volumes of 
chloroform. The residue solution was titrated again to a pH of 4.5 
and after incuba.ti<;>n with ~-glucuron:i,dase/a.ryl sulfatase, . the 
14 
lib.era.tad phenolic metabolites were. extracted twice with three volumes 
ot chloroform at pH 9.p. Each chloroform solution was concentrated to 
a volume of about 3 m~. 
A procedure developed by Talalay ~ al. (40) in 1946 f'or ~-glu-
cwonidase/aryl sulfatase release of products formed by ~onjugation of 
phenolic metabolites and aryl sulf'onic acid was used. Two ml of pH 4,1;; 
metabolic fraction and urine were mixed with equal volumes of acetate 
buffer pH 4.5. After addition of 0.05-0.l ml of e-glucuronidase/aryl 
sulfatase (10,000 units/ml), the mixture was inc~bated in a shaking 
water bath for 18 hours at 37oc. 
Liquid Scintillation SpectrometrY 
The total· radioactivity of each fraction of either chloroform 
soluble phase or ag,ueous phase, which was obtained as described above, 
. was determined in, a. Liquid Scintillation Spectrometer, Tri-Carb Model 
527, Paclcard Instrument Co, .A, sc:i,.ntillation solvent system developed 
by BTay (41) was used in this study. One tenth or one ml of sample was 
. ad~ed to 15 ml of Bray sol vent i.n the · liquid scintillation counting. 
The Bray filOlvent was prepared by· die solving 60 gm of na:phthalene, 4 gm 
of PPO and 200 mg of POPOP in 100 ml of methanol, 20 ml of ethylene 
glycol and para-dioxane to m~e l liter. !,. qµench:ip.g correction factor 
was determined by recounting all· samples after addin~ l. ml of 3H- · 
ohlQrpromazine solution which contained 2.6 mg of' 3H-chlorpromazine in 
100 ml of Bray solvent.· · Th.is solution was adde.d so that the radio-. 
ac ti vi ty of the blank was· increased to about. l, 000 cpm. In this study, 
16 
the u:rine collected from control rats was used aa a blB.l;l.k. 
Identification of Metabolites 
An 9rttempt was made to. deterini:ne whether there was e, cleavage at 
the position of the rin.g N and/or the S. . If this process· occurred, it 
·, r • 
was proposed that there would be or~hanilic acid, aromatic amines and 
. their derivatives, and sulfonio acids present as metabolites. A qu.an-
titative determination was also devised for unm.etabolized chlorpro .. 
mazine and hydroxylated chlorpromazine. 
~ .. Layer Chromato;raphy 
In·this study~ the thin-layer plates were prepared by adding 61 
ml of watEiir to 30 gm of Silicl;l. Gel G. The layer thickness wafl 50 P.· 
Eastman Kodak thin .. laye;r ch:romagram sheets were.also u1:1ed in this study. 
· Solvents 
. Chromatograms were developed in two. solvent systems by an. ascend-
ing technique. Other solvent 1;1ystems were u1:1ed1 but these two systems 
were the best. Solve2?-t l: . ethylac:,etate:meth~ol:dlethylamine (14:4:5) 
(17). Solvent 2: n-.1:;>utanol:acetic acid:water (40:10:50). · Solvent l ·· 
was adequate for the·separation of nori-.polar metabolites, while aromatic 
amines and other compou]lds gave an accepta'ble separation ·in solvent 2. 
· Spray Reagents 
Chlorpromazine and its derivatives can be detected by a spray 
reagent consisting of sulfuric acid :water : 95% ethanol (l:1:8) (23); · 
the spots were a pink.or purple color. 
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Aromatic amines can be detected at concentrations as low as 0.1 
pmolee in a test tube color reaction by a method described 'Qy Hearn 
--
et al. (42). This reagent can also be used as a spray and the sensi-
tivity is still very good for detecting concentrations as low as 0.01 
).unoles on thin..,.layer chromatograms. Qn.e other advantage of this re-
agent is that each amine has its own characteristic color, and.this 
changes to a !'ina.l stable color after wa.r:ining from 30 seconds to 1 
minute. This reagent was prep~edby dissolving 10 gm of ammonium 
eerie nitrate in 100 ml of 5% nitric acid. Other reagents were tried, 
but none 11ere as sensitive and simple 9i,s this reagent. A dichromate-
sulfuric acid 1:1olution, in which 5 · gm potassiwn diohromate was dis-
solved in 100 ml of 40% aqueous sulfuric acid, was also valuable for 
identifying primary; 1;3eoon:dary, . and tertiary wni:nes. 'by vari.ous colors 
(43). P:r;Lmary amines gave a blue color immediately, secondary amines 
gave a yellow color which changed to blue after 10 minutes, while 
tertiary amines g9i,ve light yellow colors. Sulfoxides, sulfones, and 
sulfonic acids·were detected as purple spote on thin-l~er chromato-
grEU11S under ultraviolet l,ight. No 1:1uital;ile spray reagent was found 
fox- sulfoxides and sulfonic acids. However sulfones c~n be detected 
l>y an iodine spray solution: ( 44). · · This reagent was prepared by dis-
solving 0.3 gm of iodine in lOO·ml of.aqueous 5% potassium iodide 
solution. 
Preparations of Sample~ ;for Detection of Non-Phenothiazine Metabolites 
. - .........,.. . . ~. •, 
The urine· col,l~cted on the first and seqond days from three rats 
administrated. 3H"'.'cp.lo:i;-prom:azine w~ pooled !'or each' r.at and concentrat ... 
· ed with· a rotary evaporator until a volume of about 3 ;ml was obtained •. 
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Two extractions with 3 volumes of ohlo.rofo:rm at pH 11 (fraction 4f were 
made.. Fraction A would contain free aromatic amines. Concentrated HCl 
was added to the aqueous phase (fraction B) until a concentration of 
20% HCl was obta.in~d, and then hydroly!'JiS v,itjl refluxing was conducted 
for one~d half hours. The :resulting solution wa,s .evaporated to d:ry-,. 
ness under reduced pressure and 50 ml of deionized.water was added. 
This was evaporated to dryness again to remove most of the HCl. The 
residue was dissolved and transferred, with a small amount of via ter, 
into a beaker. After adjustment of:. the pH to 11, the liberated aro-
matic amines (fraction C) from conjugation was extracted twice with 3 
volumes of chloroform. This residue (fraction D) was adjusted to pH 5. 
All three fractions were th.en dried and 0.2 ml of methanol was adde~ 
to f,raotions A. and C ~nd 0.6 ml of H20 to fractions B and D. A system 
of color tests was arranged and thin-layer chromatography n.s utilized 
for qu.alitative identification.of meta.boliteEJ~ 
· J>rep!U"aticinEJ .2£ :sam;gles for Assay of Phenothiazine Metabolites 
Both urine which was colJ.e cted o;n the first, second, and third 
days !llld li'\rer microsomal incubated. solutions were used f'or the. iden-
ili.t'ication stud,y of phenothiazine metabolites. ·. The procedures were 
the same as that d,esoribed in the balance &1tl.i,dy. Samples of' pheno-
thiazine meta'boli tea were obtained . in the three chloroform extracts at 
pH 13, at pH 9.5 and at pH 9.5 after incubation with S-glucuronidase/ 
aryl sulf'atase •. The chloroform e~t;racts of s~pleswere evaporated to 
dryness by passing dry air over the liquid surface. Two tenths ml of 
CHC13 was added to each sample residue BJ:ld these extracts were used for 
qualitative identification a.nq ~uantitative studies~ 
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Identification of Non-Phenothiazine and Pp.enothiazine Metabolites 
....... ,............ 
Non,-ph&nothiazine me~boli teE1 were identified b:y color tests in 
test tube reactions and by thin-layer chromato~raphic techniques. In 
the thin-layer chromatography studies, orthanilic acid, chlorobe?J.zene-
sulfonic acid, and other.aroma.tic amines·whi,ch were considered to be 
possible metabolites were used as. references. On the. other }land, in 
the phenothiazine ide:!ltification studies, the compounds ~sed for ref-
erences were the 7-hydroxychlorpromazine, chlorprqmazine, and· chlor-
promazine N-oxide. Since the interest in this study was on the hydro-
xylated metabolites and the non~:J?henothiazine metabolites other pheno-
· thiazin" unknown spots were not identified. · 
~uantitative Studies 
Street (45) found that the colored solution formed by chlor-
promazine in 50% sulfuric acid exhibited, a. characteristic ultraviolet 
' . . 
absorption spectra. Based on this observation Kurland et al. (46) 
' ' . ...-- -
devel.?ped a quantitative assay for chlorproma~ine. In this. study, 
their method was followed and a standard curve was prepared for chlor-
promazine and 7"'.hydroxychlorproma.zine, then the unchanged chlorpro-
• mazine e.nd the 7-hydroxychlorpromazine formed was determined. The 
procedure for this E;tudy was: a.1], thesampl.es were dried, a volume 
of O. l .ml of chloroform was added and 25..,;50 X of' each sample was spot- · 
ted on th~n-larer chromatographic shee·ts. The sheets were developed 
in a solvent system consisting of ethylacetate .: methanol :. diethyla-
mine (14: 4 s 5) by an ascend;l.ng tech,nique. Chlorpromazirie and 7-
h.ydroxyohlorpromazine were detected by Spraying with the sul.furio acid 
reagent, and they prodµoed a pink iuid pu:r.ple color respeot:iveiy. . All 
the.colored aref1, of this spot was removed and the color was extracted 
with 3.5 ml of 50% sulfuric aoid. Centrifugat;i.on was used to remove 
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the silica f;;el. The !i!,.bsorl;>~cy of the co;lored acid extract was deter-
nµ.ned in a Beclana.nri. D. U~ Spectrophotometer~ A solution of 6o% sulfuric 
acid was used·u the bl~k. The Cary 14 Recording Spectrophotometer 
was used to determine the absorption spe()tra of reference oompounds a,nd 
isolated metabolites. 
RiSUI.,TS AND DISCUSSION 
Balance Study 
As has been indicated in the literature review the metabolic modi-
fications of chlorpromazine are manifold and include sulfo~idation, 
demethylation, ring hydroxylation and conjugation,, and oxidation at the 
terminal nitrogen of the side chai,n. Since any pomb:1,:na.tion of these 
reactions may occur. a theoretically l~ge ntUJ1'l;>er of metabolites could 
result, Nq single metabolite :l,dentified to date accounts for more than 
8-10% cif ~e dose (1). Emmerson et al. (10) have shown that appro;xi-
. ......- .. 
mately 40% of the adminis~red radioactivity was excrete.d by the rat in 
~e urine when. $5s-chlorpromazine was administered .. · In this study, 
when the rat was administered '3H-ohlorpromazine,. results similar. to 
. . . 
those repo;rted by Emmerson et al. we:re obtained •. · About 35 to . 40% of 
- • .......,., I 
the admi~iste;red radioa.oti vi ty appear~d in the urine w'i thin five days 
. . . . . .... 
(Table i). It is shown inTa.ble I ancl II ·~at the majo~ portion of 
admirp.stered radioactivity was in the sc;>lids of tU"ine,. while the vola~ 
tile phase, 'which mi~t contain 3H20, R-ciI3o, etc. accounted for only 
. 3 ·.· 
0,1% of the :a-chlorpromadne. As stated the major part of the radio-. 
aoti vi ty was excreted by ~e rat during : the f':i,rs t day, while after the 
fourth day less than 2% was excreted. · It is of interest that in this 
· · stu.dy, although half of th(:) dose was adminiatered on the first day ·and 
the remainder on the next day, an accumulation of radioactivity on the 
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TABLE I 
RADIOACTIVITY IN URINE EXCRETION FROM RA1'S 
CPZb 
Activity Observed Total 
a· Body Day ·Activity 
Rat Weight Dose Collected l 2 3 4 5 Observed Rec_overy 
grns ny.ic I!JlC 11J.l.C mµc m,µc ny.ic m,µo % 
l 452 690 Sol.id 158.0 34.3 32.9 9.6 5.6 242 .. 8 35.2 
Liquid 0.7 0.6 0.4 0.4 0.4 
2 4157 764.6 Solid 199.8 80.9 15.9 2. '1 3.3 305.4 40.0 
Liquid 0.6 0.6 0.6 0.5 0.5 
3 350 298 Solid 73.7 20.7 13.6 2.6 112.0 37. 6 
Liquid 0.7 0.3 0.2 0.2 
4 34-0 298 Solid 70.2. · 19.5 · 9.2 1.4 101.5 34.l 
Liquid 0.7 0.3 0.1 0.1 
5 360 410 · Solid 105.7 32.3 12.0 6 .. 2 157.2 38.4 
Liquid 0.4 0.4 0.1 0.1 
aRat l, 2~ were injected with half of the dose on the first day, and the remainder on the next da_y. · 
'haat 3, 4, 5., were given the entire dose on f'irst day .. 
I;\) 
I-' 
TABLE II 
PERCENTAGE OF RADIOACTIVITYa EXCRETED IN SOLID PHASE OF URINE FOR EACH DAY 
Total 
Radioactivity· Daz 
Rat. Observed l 2 3 4 
IllJlC % 
" 
% % 
·1 242.:S 65.2 14.l 13.5 4.0 
2 306.4 65.5 26.5 5.2 o.9 
3. · 112.0 66.6 18~5 12~0 2.3 
4 101.5 69.2 111.2 9.1 1.4 
5 151.2 67.2 20.5 7 • .S 3.9 
aBased on total radioactivity observed. 
5 
% 
2.3 
0.1 
N 
t\) 
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s.econd day in excreted urine wia.s not observed ( Tabl~ II). 
Posner (18) had observed that gluouronides were the major excretory 
products in man rather than sulf'oxio.es. In this study with 3H-ehlor..;, 
promazine, it may be seen from Table III that this is not the case with 
the rat. Fractionation of urine from rats receiving chlorpromazine, 
based on radioactivity of each day observed, showed over 50% of the 
a.dminist(;'red radioactivity was iJ;l the chloroform extrMts of urine at 
pH 13, while less than 7% was in the chloroform extracts of urine at 
pH 9.5 before and after incubation with ~-glucuronidase/aryl sulf'atase. 
As shown in Table III, the amount of "free" and conjugated phenolic 
metabolites were increased on the second day, a,lthough the radioactivity 
in this fraction was low. In spite of the s;mall amount of "free" and 
conjugated phenolic metabolites, it is of interest that both fractions. 
are almost equal, and the degree of glucuronide conjugation was in-
dependent of the day after drug administration. This suggests that 
there may e,cht an equilibr:j.uni between "free•• an.d conjugated metabo-
lites, and the equ::llibrium <;}Onstant is qlose to unity. 
If we look at the rad::loact~:vi ty of the aqueous urine residue 
( Table III), whtch is obtained after incubating with ~ -glucuroniclase 
/Eµ"yl sulfatase, the activ:j.ty of.3H was alpiost negligil;lle. These re-
sults are quite different from tllatof ntj.ce receiving 35S-~hlorprc;,-
ma.zine. -VVhich Christensen et al. (11} found with mice 3-5% admin:j.EJ-
trated radioactivity was in the form of' free sulfate, and. 23-48% in tlle 
"comb;i.ned sulfate" .form. This i:nd:i.catt:ls that the phenothiazine. ring in 
ch;I.orpromazine is possibly more stable in rats than in mice. 
As described in the literature review. Gillette et al. (12) 
. --..- -
. . . 
observed that liver microsomes had many enzyme systems oo;mcerned.with 
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TABLE III 
RADIOACTIVITY OF URINE CHLOROFORM EXTRACTS AND RESIDUE 
Distribution of Radioactivity 
Enzyme a: Incubated 
pH 13 pH 9.5 pH 9.5 
Day Total CHC13 CHC13 CHC13 Water 
Rat Collected Activi~ Extracts · Extracts Extracts Residue 
:mµc mµc mµc mp.c mµc 
1 l 158.0 109.6 7.0 10.1 1.4 
2 34.3 16.5 5.3 7 .4 1 .. 9 
3 32.~ 17,4 3.1 2.0 o.8 
2 l 199 .a. 139.0 J.3.9 14.l 5,0 
2 80.9 48.3 6.5 8.4 5.7 
3 15,9 9.3 J..l 2.0 0.5 
Distributionb of Radioactivity as. Percent of Total Per Day 
% % % % 
l 1 69.4 4.9 6.3 0.9 
2 48.l 15,5 21.6 5.5 
3 53.0 9 .'!l, 6.1 2 .4 
1 69.q. 6.9 7.0 2.5 
2 59.9 8.o 10.4 7.1 
2 
3 58.5 6.9 12. 6 3.1 
a ~~Glucuro~idase/a.ryl sulfatase. 
bcalculation based on total radioactivity excreted of each day 
observed. 
· the meta.boli,sm of drugs, IUld these enzyme systems had the remarkable 
requirement for both reduced NADJ> and oxygen. · In the in vitro experi• 
ments in this study, glucose-6~phosphate and gluco~e-6..:.phospha.te dehy-
drogenase were added to microsomal fractions to serve as a NADPH 
generating system. 'The NADPH generating system was not required with 
the 10,000 X G supernatant and the homogenate. As in the method de.;. 
scribed by Gillette et!!· (l2), niootina.mide wa1;1 added to protect 
NADP and Mg++ n.s a required ion. The enzyme assay 1:iy1:1tem for cp.lor.-
promazine oxidase is shown in Table IV. 
When 3H-chlQrpromazine was incubated with pig liver microi:iomes, 
the radioactivity distribution from the fractionation of the incubated 
solution 1ras similar to that.of urine, except with the conjugated 
metabolites. · As sho'W?l in Table V, chloroform extracts at pH 13 still 
contained the major portio~ of the administered radioactivity. The 
ra.dioaotivi ty .in the. aq.1,1eous phase after incubation with ~ -glu~mr• 
onidase/a,ryl sulfatase was negligible~ With .the pig liver microsomal 
fraction, the degree of glucuronide cc;mJµgation was greatly decreased 
and was approximately one tenth of that. of free. phenolic metabolites. 
It might be possible t)la;t there exists a slow step ;in the conjugation 
reaction so that a one h,;,ur incubation was not enough time for a com-
. . 
·. plete reaction. There . might ala O •. be a. laok of . the. enzyme system' or· 
cofactors for this reaction in pig liver mtcrosomes, or the reaction 
: . . 
may occw in another tissue •. Comparing Table. V with Table III, it is 
evident that the swn of free and conjugated phenolfc metaboli tea in 
the in vitro. study with pig l,iver and the ;f'irst days rat urine are 
similar. Al.though the degree of glq.c~onide conjugation was different 
between these two experiments, the rate of hydroxylation might be the 
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TABLE IV 
· cHLoRPabMAZINE . OXIDASEa AaSAX SYSTEM 
Item 
Supe~atantb 
Hc>1noge~ateb. , 10,000 x G. . Miorosomeb 
Chlorpromazine 
NADP 
MgC12 
Niootin,amide · 
Gluoose~6-phospha te d,ehydr9genase 
Neutralized semioarb.azide 
0.2 M phosphate l;>utf'er pH 7~4 
JmJ,oles 
5 ... 
0.8 •. 
~o 
?0 
25 
•. 26 · 
l ml 
·, . . . . 
pmoles 
5 
o.a 
20 
50 
26 
25 
a.Ring hydroxy~a,t~on at the ,f ... J?O$itj,o;nof' the phenothiazine 
nucleus. · · · · 
. . . 
µmoles 
5 
a.a 
20 
50 
25 
2 uni ts 
25 
l ml 
bA volume. of' tis~ue pr~pa.rat~on equiv~le~t.to 0.5.g ot fresh 
liver was added, a volume ot water a:.dq.ed. to ea.ob'. mixture to make the 
volume up to f;,.8 ml. · · · · · · 
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. TAJ»,E V. · · 
RAOIOACTIVITY OF CHLOROFOlUi EXTR4CTS OF PIG LIVER 
. . l4ICROSODS INCUBATED WI1R· 3H.,.CHI,OJU>ROMAZINE 
RacUoaot:l.ve 
Distrib'1tion 
I)istribution ' 
Total 
Aoti_vit,· 
;mµc 
242 
pH 13 
CHCl3 
Extracts• 
~o-· 
l81.3 
% 
7_5 
pH 9.5 
,, 
. -.CHC13 . 
. Extracts 
DIJlC . 
'' 
29.8 
' %: 
12.3 
Res14ue Inoubateq 
With Enzymea 
pH 9.5 Residue 
.. CHC13 . .Aqueous 
Extracts Phase 
mµc Jl9.l.O 
3.0 4.2 
% % 
1.2 1.7 
. . 
same. The comparison of rat urine metabolites w:1.th pig liver microsome 
metabolites may Jl.Ot be val;ld. 
Metabolj;:te. Id.entif:LcatioJi Studr 
Although no evidence h¥ been obtained that there i;s a cleava.ge 
of the phenothiazine ring in chlorpromazi~ me~bolism., thia might 
occur as shown in 1igure 2. In Table I, II, and III, there is only 
about 1~2% of adm.inbtered radipaotiv;lty left in the aqueous urine 
residue. In other words, when three rlil,t urines were pooled (Table I}, 
there wa.s an ~ouri.t of com.pound in the wa.ter residue equivalent to l 
)llllOle or abQut 0.36 mg of ohlorprom.azine •. These concentrations are 
with;ln the detectable range of cQlor tests Q.Ud_thin-;tayer chrom.atog .. 
raphy. However:,-as shown in Table VI,.the suspected com.pounds were nc;>t 
detected~ The ai-o:me.tio amines, orthaniU,c acids, chlo:i;-obenzenesulfonic 
acid and other sultoni~ ac:i.ds tests were.negative. These results do 
not prove th~t ~ing cleavage does· ~ot occur as a high salt co~centra.tion . 
. . 
in th, samples !llld other technique problems were present. On the other 
hand, there m.~ b~ so many dif'te:rent.kinds of com.pounds present that 
· . each oom,pound. could only be· present. in a concentration to low for de-
tection. 
7-.H;ydroxychlorprom.azine . arid wµne~l:iolized cblorprom.azine were . 
identified j,n bo.th rat urine and incubated pig li '"'r subcellular fraq- · 
. . ' . . 
tionst but as 1:1hown in Table. VII, the pa~ern f'or other metabolites 
. . .. 
appears to be diff'erc,,nt~ In chloroform ex~a_cti'I at pH )3, there was 
a pi:nk ~identified spot at Rf O. 72 in :rat wine, while the s9lution 
incubated with pig liver suboellul!U' .fraotiQn, .f~Ued to $how tM,s 
.meta.bolite, but ·di_d show a pink ~pot o!' chlorproma.zine N-oxide a,.t Rf 
s 
N 
I 
-CH2 
I -
CH2 
I 
c~ I 
/N......._ 
CH3 CH3 -
Chlorpromazine 
Cl 
©r~H 
Orthanilic Acid 
; /_--_H2S03_-rA __ __ 
- ~~l ~ Para~Chlorobenzenesulfonic acid 
R. 
~.· ·_fnlo· _-__ -- __ H 
- - ~N-R 
~ - · _ Amines or 
_ ~- Conjugates 
. . ©rS0382 
Sulfonic Acid 
or-Conjugates 
Figure 2. Proposed Ring Cleavage of Chlorpromazine With Products 
That May Result From This Prooess 
N 
(0 
TABLE VI 
NON-PHENOTHIAZINE METABOLITES IN RAT URINE: TESTS FOR AROMA.TIC AMINES, 
ORTHANILIC ACID, PARA-CHLOROBENZENESULFONIC ACID 
pH Chloro- pH 11 
pH 11 pH 11 form Extracts Aqueous 
Rj-Val ue of 
Reference com,ed 
Chloroform. Aqueous After Acid Phase Arter Sol vent . Sol vent 
Extracts Phase Hydrolysis 
.. 
Aromatic Amine Ne_gative Nega.tive Negative 
Orthanilio Acid0 Negative Ne_gative Negative 
Para-chlorobenzene--d 
Sulfonio Aoid Negative Negative Negative 
a.Solvent I: ethylacetate : methanol : diethylamine (14:4:5). 
bsolvent II: n-butanol: aoetfc acid: H20 (40:10:50). 
Hydrolysis Ia 11b 
Negative 
Negative 0.15 0.27 
Negative 0.33 0.44 
0 Detected by spraying with ammoniun eerie nitrate in 5% nitric acid, pale orange--brown (final color). 
dDetected under ultraviolet light (short frequency). 
CN 
0 
TABLE VII 
IDE:NTIFICATION OF CHLORPROMAZINE METABOLITES IN RAT URINE 
AND INCVBATED SUBCELLULAR FRACTIONS FROM PIG LIVER 
First Chloroform Extr~ct at pH 13 
31 
Ra 
t Col orb With H2so4 
Reagent 
Probable IdentityC 
Urine (1st. day) 
Subcellulard 
Fractions 
0.82 
0.72 
0.81 
0.26 
0.1 
pink 
pink 
pink 
pink 
pink 
cpze 
unknown 
CPZ 
CPZ-eN-0x:j.de 
unknown 
Second Chloroform Extract at pH 9.5 Before Incubation 
With ~-Glucuronidase/Aryl Sulfatase 
Urine 
firE1t day 0.85 pink unknown 
0.67 purple 7-hydroxy CPZ 
second. day 0.86 pink unknown 
0.66 purple 7-hydroxy CPZ 
0.21 pink unknown 
0.09 pink unknown 
Microsomes 0.67 purple 7-hydro:xy CPZ 
0.58 yellow unknown 
0.21 pink unknown 
0.10 pink unknown 
TABLE VII (CONTINUED) 
ThirQ. Chloroform Extrac.t at pH 9.5 After Incubation With 
~-Glucuronidasel.Aryl Sulfatase 
Urine 
first day o.ao 
0.66 
0.10 
second day 0.82 
0.66 
0.10 
· Miorosome 0.66 
0.10 
Color 
With H2so4 
Reagent 
purple 
purple 
pink 
purple 
purple 
pink 
yellow/purple 
pink 
Probable Identity 
Qllknown. 
7-hydroJcy CPZ 
unknown 
unknown 
7-hydroJcy CPZ 
unknown 
suspected 
7-hydroxy CPZ 
llD.know.n 
32. 
a.Eastni.a,n Chromagram Sheets were used, developed in ethylacetate: 
methanol1diethylami,ne (14:4:5). 
bH2so4 :water:96% ethanol (1:1:8). 
~Ch;LorprQmazine and 7-hycu-oxychlo:rpromazine as :references. 
. d~a:rosomes, b,omogen4:1,te~ and supernatant (10,000XG) all show the 
same. pattern. 
ecpz ""ohlorprom,azine. 
0.26 and an :u:nidenti.fied pink spot .at Rf 0.10. A more complicated 
pattern was observed in chloroform extracts in the second days urine 
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at p:ij 9.5. Two metabolites in the first days urine in the nonconju-
gated form, and three metabolites in the conjugated form were observed. 
Both extracts before and after incubation, contained 7-hydroxychlor• 
prom.azine, the other unknown metabolites showed a different color a.n.d 
Rf value. The second days urine showed two more l.Ulknown metabolites 
with pi~ colors in nonconjugated forms and .the same for conjugated 
metabolites. However microsomes showed a similar result relative to 
the second dEo/s urine sample with nonconjugated metabolites, but showed 
only two spots for conjugated m~taboli tes. It is of interest that 
microsomes did not show the unknown spot with Rf 0.8-0.86 as seen in 
urine with nonoonjugated and conjugated metabolites. 7-Hydro:x:ychlor-
promazine was positively identified in rat ~ine and in the solution 
incubated with p;i.g liver subcellular fractions in both nonconjugated 
and conjugated. '.Lhis suggests that 7-hydroxychlorpromazine is an im-
p~rtant metabolite and may be the major one. 
Quantitative Study 
Ultraviolet and visible spectra were made for cblorpromazine and 
7-hyd,~oxychlorprom.az ine in 50% su],fur;i.o acid ( see Expe:rimen tal L 
which were shown in Figures 3 and 4. The wave length of maximum ab-
sorption was determip.ed. As shown in Figure 5, the standard curve was 
made at 560 millimiororis for the quantitative determination of both 
.l,l?lliletabolized ohlorpromazine and 7-hydroxychlorpromazine. 
The results of a quantitative determination are shown in Table 
VI;l:I, To ooni'irm these quan ti ta ti ve results, it is necessary to compare 
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Figure 3. The Ultraviolet Spectra 0£ Chlorpromazine and 
7-Hydroxychlorpromazine 
34 
340 
0.5 
0,4 
0.3 
A 
0.2 
0.1 
400 440 480 520 560 
Wave Length mµ. 
35 
7-Hydro:x:y-
chlorpromazine 
Chl orpromaz ine 
600 640 680 
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'.CABLE VIII 
QUANTITATIVE DETERMINATION OF UDij}TABOLIZED CHLORPROMAZINE AND 
7-HYDROXYCHLORPROMAZINE ~OM RA.X URINE AND PIG LIVER 
SUBCELLULAR FRACTIONS 
Urine0 
.first d~y 
seoond clay 
third day. 
Homogen~te6 
Supernat1;1.nte 
(10,000XG) 
M. e iorosomes. 
Urunetabolized 
Chlorpromazinea 
% 
;I.0.9 
trace 
unde tee table 
45.0 
46.6 
67 ~o 
7-l!ydroxy- b 
Chlorpromaz ine 
% 
d 0.38 4d B 0.19 
A 0,14 
B 0.11 
A undetectable 
B unq.etectable 
A 1.5 
B \lndeteotable 
a.First chloroform extracts at pH 13 were examined. 
bseoond and third chloroform e~tracts at pH 9.5. 
0 9-10 mg o.f chlorpromazine was injected to rat~ an average value 
was ta.ken from two rats • 
d:4 and B represent the chloroform extracts at pH 9.5 before and 
aj'ter incubated with ~-glucuronidase/aryl sulfatase, respectively. 
el. 78 mg of chlorpromazine was incubated for l hour. 
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thii, ~ata in Table VIII with 'l'able III and V. The umnetabolized 
· chlorpro~zine acco~ted fqr 45-67% of the :inetabol,i tes from pig liver 
suboellular fraot:l,.o:ns. Since the metabolism ot. chlorpromazine se1:;1ms to 
be incompli,te for mj,crosomes · this. suggei;sts that added giucose-6-phos-
phate and glucose-6-phosphate dehyd~ogenase were not sufficient to 
replaQe the soluble fraction cofactors. Also, the one~hour incµbation 
may not permit complete reaction, since with t;h.e in vivo study :i,n the 
. .· --
rat (Table VIIIL unmetabolized chl,orpromazine represented only 11% of 
· the adminiatered dose. 
As shown in Table VIII, the resul ti, of the q,uanti tative deter-
mination agree with the distribution of administered radioact\vity in 
chloroform extracts at pH 13 in the bal$l,Lce studiEis (Tables III and V), 
especially for microsomes. ThtHH:'l results suggests that there are some 
iinporta.n.t metabolites other than u.nmetabolized ohlorpromazine in the 
. . 
· chloroform extracts at pH: 13, e1;1pecially with rat urine. 
·There was a higher co~oentration of' 7-hydroxychlorpromazine i:µ. t}ie 
free form tha.n. in the conjugated form ~n the :first days urine.· However, 
in the Qala.n.oe study conju,gated metabolites had about the same radio-
activ:i, ty as that of' f?"ee metabolites. Tll,is indica,tes th~t there were 
other xmporta.n.t metabolites for conjugation. The thin-layer chroma-
tographic resu:j.. ts pr<>vided evidence ·.for this ~oint ( Table VII). The 
percentages of 7-hyc::J.roxychlorproma.zine found :1,.n the second day urine 
. . . 
agree~ with the results shown in Table I;U and VII (Table VIII, line 2). 
When ~5S .. chlorpromazine wa1;1 given 'to the rat, Emmerson et al, (10) 
--
were able to account f'or 12% of' the dose in urine as unmetabolized 
drug. In this study, it was shown. that 11% of the u.nmetabolized chlor .. 
promazin,e was excreted in the first days urine while only traces .were 
39 
opserved in the second day, a.nd it was undet~i:,tab:).e in the third day. 
CHAPTER V 
The metabolic fate of administered 3H-chlorpromazine has been 
studied in the rat anq pig. Urinary metabolites from the rat were 
examined to establish the relative importance of the 7-hydro;xychlor-
promazine metabolic pathway. These samples were also analyzed for 
met'-bolites which would result from cleavage of the phenothiazine ring. 
In vi trQ studies included incubation of the. tritium labeled drug with 
:rat and pig liver homogenates and pig liver microsomes. Gluouronide 
complexes of chlorpromazine metabolites were isolated as a group after 
incubation of urine samples wi.th ~-glucuronidase. An assay system for 
the enzymr;, which hydroxylates the phenothiazine ring of ohlorpromazine 
has been devised. 
:F'rom 35 ... 40% of administered radioactivity appeared in the ur;l.;ne 
within'5 days. On the bash of total excreted 3H,. 65% was excreted on 
the first day while after the f0urth less than 2% was observed. The 
solids of urine contained the major portion of the radioactivity while 
the volatile 3H metabolites contained leu than 1% of the total activ-
ity. ~~action of µrine samples at adjusted pH values gave the fol-
lowing results: ;First extraction with chlorofcmn at pH 13 showed 
56-69% of' the total 3H was pi'ese:n,t as unohar,iged ohlorpromazinr;,, chlor-
p:roma.zine-,.N-o:x:ide and the sulfoxide, chloroform extractio;n at· pH 9. 5 
before and aftE,r incubation with f>-g;luoiironidase (at :pH 4.5) showed 
40 
4:l 
the nonconjugated an4 conjug-.ted phenol;i.o metabolites were about eqt.ial 
. . 
in concentrat;l.on tor ~ach days uri:p.e sampl;e; the activity remaining in 
the urine residue after the three ex"b'actions describeq above was negli-
gible~ 7 ... Hydroxychl.orpromazine was iden,tif'ied as the phenolic metabo-
lite in ra,t urine. ;rt was present in both oonJugate and nonoonjugate 
forlllS. 
Pig liver rnicrosomes shc:>Wed most of the aot:i,vi ty in the chloroform 
extracts from samples adjusted to pH 13. Thin layer chromatography of 
the pH 9.5 chloroform .extracts of this same sample revealed the pre-
sence of. Jlydro~chlorpromazine. These samples contained less the.µ 2% 
of the drug as the conjugated (ierivative. The aqueous residue of the 
microsomal fraction after the extractions.described above contained 
about 2% of tb,e 3H activity.· 
lfo evid:enoe waa obtained to S'\lpport the exis ta.nee of a pheno-
thiazine ri~g cleavage. metabolic 1;3ystem ;in the rat. · The teists for· 
· aromatic amines and th.eir. conj~gates, sul.t'onio acids and orthanilic 
acid were JJregative. 
An assay system :f'or the microsomd enzyme whicll oats.lyes the ring 
bydroxyb.tion q:f' chl'orpro:rn.azine. has been developed by adaptation of a 
method proposed by other worl<:ers :f'or the N-oxid,ase enzyme~ 
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